Clinical Trials
4 trialsNCT05613088 2026-04-30
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT07545460 2026-04-22
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06994195 2026-04-20
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04516447 2026-04-07
MUIR
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Recruiting